Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6285923 | 0.73 | ESR1 (0.48) | SIGMAR1TDP1KDM4EMEN1KMT2A | |
| SCHEMBL6283150 | 0.73 | PPARG (0.58) | — | |
| SCHEMBL6279738 | 0.70 | RAB9A (0.49) | SIGMAR1SMPD1MEN1KMT2AATM | |
| SCHEMBL2355634 | 0.67 | LTA4H (0.75) | SIGMAR1TDP1LTA4HMEN1KMT2A | |
| SCHEMBL10484073 | 0.67 | ESR1 (0.56) | KDM4EMEN1KMT2AATML3MBTL1 | |
| SCHEMBL11775034 | 0.66 | LTA4H (0.67) | SIGMAR1LTA4HMEN1KMT2A | |
| SCHEMBL17150143 | 0.66 | SMPD1 (0.78) | SIGMAR1KDM4ESMPD1MEN1KMT2A | |
| SCHEMBL13150788 | 0.66 | SIGMAR1 (0.88) | SIGMAR1SMPD1 | |
| SCHEMBL14450490 | 0.65 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL10484125 | 0.64 | ESR1 (0.60) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911468-B2 | Tyrosine phosphatase inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-31 | — | — | US | disclosed |
| EP-1284260-A1 | TYROSINE PHOSPHATASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144338-A1 | Tyrosine phosphatase inhibitors | PTPRC, PTPN1, PTPRM | SIGMAR1 2310/4885TDP1 1772/4885KDM4E 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.